A phase I study of osimertinib with bevacizumab and randomized phase II study of osimertinib with or without bevacizumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (WJOG8715L)
Phase 1
- Conditions
- ung Cancer
- Registration Number
- JPRN-UMIN000023761
- Lead Sponsor
- West Japan Oncology Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 87
Inclusion Criteria
Not provided
Exclusion Criteria
1. Subjects with interstitial lung disease 2. Subjects with high risk of bleeding 3. Positive test for hepatitis B virus antigen
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Phase I: safety Phase II: progression-free survival
- Secondary Outcome Measures
Name Time Method Overall response rate, time to treatment failure, survival time
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie the synergy of osimertinib and bevacizumab in EGFR T790M-positive NSCLC?
How does the combination of osimertinib and anti-VEGF therapy compare to standard third-generation EGFR-TKI regimens in resistant NSCLC?
Which biomarkers correlate with improved progression-free survival in JPRN-UMIN000023761's EGFR T790M-positive cohort?
What are the most common adverse events associated with osimertinib-bevacizumab combination therapy in EGFR-mutant cancer patients?
Are there alternative EGFR-TKI and anti-angiogenic combination strategies for T790M-positive NSCLC beyond AstraZeneca's osimertinib regimen?